Aphaia Pharma

Aphaia Pharma is a Swiss clinical-stage biotech focused on revolutionizing the treatment of metabolic diseases through a novel oral drug delivery platform. Its lead candidate, APH-012, is a proprietary oral glucose formulation designed to activate nutrient-sensing cells in the distal small intestine, triggering a comprehensive hormonal response to control appetite and glucose metabolism. The company is currently advancing APH-012 in two Phase 2 trials for obesity and prediabetes, building on positive early clinical data. Led by an experienced team with deep industry and scientific expertise, Aphaia aims to provide long-term therapeutic benefits with minimal side effects by restoring the body's natural physiology.

Precision-targeted oral drug delivery platform designed to activate nutrient-sensing L-cells in the distal small intestine, triggering a synchronized release of endogenous enteroendocrine hormones (e.g., GLP-1, GIP, PYY) to restore metabolic balance.

Aphaia operates in the highly competitive metabolic disease space, dominated by large players with GLP-1 receptor agonists (e.g., Novo Nordisk, Eli Lilly). Its primary differentiation is its oral formulation and its aim to restore a full spectrum of endogenous hormones, positioning it against both current injectables and other oral therapies in development. Success will require demonstrating superior or complementary efficacy/safety.